Following the trading update on 14th Sept we have reduced our Immunology and Bio-manufacturing forecasts. However, we remain optimistic as the Immunology offering is being revitalised with new assays and the first stirred-tank bioreactors are on track to become operational in Q1 2018, driving expected margin enhancement.
27 Sep 2017
N+1 Singer - Abzena - Forecasts revised; bioreactor installation on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Abzena - Forecasts revised; bioreactor installation on track
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
27 Sep 2017 -
Author:
Dr Jens Lindqvist -
Pages:
5
Following the trading update on 14th Sept we have reduced our Immunology and Bio-manufacturing forecasts. However, we remain optimistic as the Immunology offering is being revitalised with new assays and the first stirred-tank bioreactors are on track to become operational in Q1 2018, driving expected margin enhancement.